BioTuesdays

Tag - BTIG

Pear Therapeutics

BTIG starts Pear Therapeutics at buy; PT $12

BTIG initiated coverage of Pear Therapeutics (NASDAQ:PEAR) with a “buy” rating and $12 price target. The stock closed at $6.20 on Dec. 31.  Pear is a leader in prescription digital therapeutics (PDTs), with three...

Freeline Therapeutics

BTIG starts Freeline Therapeutics at buy; PT $10

BTIG launched coverage of Freeline Therapeutics (NASDAQ:FRLN) with a “buy” rating and price target of $10. The stock closed at $2.37 on Nov. 26. Freeline has built a next-generation gene therapy platform based on a...

Mdx Health

BTIG starts MDx Health at buy; PT $15

BTIG launched coverage of MDx Health (NASDAQ:MDXH) with a “buy” rating and price target of $15. The stock closed at $9.04 on Nov. 26. MDx Health is a precision diagnostics company that offers a portfolio of...

Aura Biosciences

Analysts start AURA Biosciences at OP, buy

Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on Nov. 22. AURA is a...

Lensar

BTIG starts LENSAR at buy; PT $15

BTIG launched coverage of LENSAR (NASDAQ:LNSR) with a “buy” rating and $15 price target. The stock closed at $7.10 on Nov. 19. LENSAR is a small-cap technology play on the fast growing laser cataract surgery market. By...

CytomX

BTIG starts CytomX Therapeutics at buy; PT $16

BTIG initiated coverage of CytomX Therapeutics (NASDAQ:CTMX) with a “buy” rating and price target of $16. The stock closed at $7.02 on Nov. 12. CytomX is a clinical-stage biotechnology company focused on developing...

Acutes-Medical-Logo

Analysts cut Acutus Medical PT to $8 and $10

Analysts for BTIG and Canaccord Genuity reduced their price targets for Acutus Medical (NASDAQ:AFIB) to $8 from $20 and to $10 from $18, respectively, but maintain their “buy” ratings, after the company reported third...

Sigilon Therapeutics

BTIG starts Sigilon Therapeutics at buy; PT $14

BTIG launched coverage of Sigilon Therapeutics (NASDAQ:SGTX) with a “buy” rating and price target of $14. The stock closed at $5.38 on Oct. 28. Sigilon is developing shielded living therapeutics (SLTs) as a “functional...

Vicarious-Surgical

BTIG starts Vicarious Surgical at buy; PT $15

BTIG initiated coverage of Vicarious Surgical (NYSE:RBOT) with a “buy” rating and $15 price target. The stock closed at $10.57 on Oct.15. Vicarious Surgical is a pre-commercial development-stage surgical robotics...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.